GeoVax Labs (NASDAQ:GOVX) Stock Price Down 4.8%

GeoVax Labs, Inc. (NASDAQ:GOVX)’s share price traded down 4.8% on Tuesday . The company traded as low as $1.50 and last traded at $1.60. 51,493 shares were traded during mid-day trading, an increase of 35% from the average session volume of 38,109 shares. The stock had previously closed at $1.68.

GeoVax Labs Stock Down 4.8 %

The business’s 50-day simple moving average is $2.14 and its two-hundred day simple moving average is $4.82. The firm has a market cap of $3.48 million, a price-to-earnings ratio of -0.12 and a beta of 2.90.

Institutional Inflows and Outflows

Several hedge funds have recently modified their holdings of the stock. Virtu Financial LLC acquired a new stake in GeoVax Labs in the 1st quarter valued at about $57,000. Renaissance Technologies LLC purchased a new position in shares of GeoVax Labs during the 2nd quarter worth approximately $333,000. Millennium Management LLC purchased a new position in shares of GeoVax Labs during the 2nd quarter worth approximately $27,000. BlackRock Inc. boosted its position in shares of GeoVax Labs by 104,042.1% during the 3rd quarter. BlackRock Inc. now owns 413,444 shares of the company’s stock worth $451,000 after purchasing an additional 413,047 shares during the period. Finally, Vanguard Group Inc. boosted its position in shares of GeoVax Labs by 112.5% during the 3rd quarter. Vanguard Group Inc. now owns 549,966 shares of the company’s stock worth $600,000 after purchasing an additional 291,200 shares during the period. Institutional investors and hedge funds own 6.09% of the company’s stock.

GeoVax Labs Company Profile

GeoVax Labs, Inc, a clinical-stage biotechnology company, develops human vaccines and immunotherapies against infectious diseases and solid tumor cancers using modified vaccinia ankara virus-like particle vaccine platform. It is developing various preventive vaccines against (COVID-19), human immunodeficiency virus (HIV); Zika virus; malaria; and hemorrhagic fever viruses, such as Ebola, Sudan, Marburg, and Lassa, as well as therapeutic vaccines for HIV, chronic Hepatitis B infections, and solid tumor cancers.